Samsung Bioepis and AffaMed Therapeutics’ Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing Global Phase 3 TrialHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 28 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Samsung Bioepis and AffaMed Therapeutics’ Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing Global Phase 3 TrialGlobeNewswireJanuary 10, 2020ReblogShareTweetShareSB12 (also referred to as AMT904) is an eculizumab biosimilar candidate for the treatment of paroxysmal nocturnal hemoglobinuriaThe only biosimilar candidate referencing Soliris® (eculizumab)1 to be granted IND approval in ChinaINCHEON, Korea and SHANGHAI, China, Jan. 09, 2020 (GLOBE NEWSWIRE) --  Samsung Bioepis Co., Ltd. and AffaMed Therapeutics today announced that the China National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for SB12, also referred to as AMT904 in China – a biosimilar candidate referencing Soliris® (eculizumab). The CTA approval grants start of Phase 3 clinical study at Chinese sites.SB12 is developed by Samsung Bioepis for the treatment of paroxysmal nocturnal hemoglobinuria and has responsibility for its global clinical trials conducted across 10 countries. AffaMed is responsible for SB12 (AMT904)’s China NDA approval based on the ongoing global Phase 3 trial conducted by Samsung Bioepis and received exclusive rights to commercialize the treatment in China and Singapore. To date, SB12 (AMT904) is the only biosimilar candidate referencing Soliris® (eculizumab) to be granted IND approval in China.“We are very pleased to announce the CTA approval of SB12 in China as it allows us to expand our global Phase 3 clinical trial to include Asian market,” said Il Sun Hong, Vice President of Clinical Operation team at Samsung Bioepis. “The clinical collaboration with AffaMed furthers Samsung Bioepis’ goal to innovate access to life-changing medicines for patients in need.”“We are delighted for this CTA approval as it further validates AffaMed’s position as a clinical-stage biopharmaceutical company,” said Dr. Nathan Pang, CEO of AffaMed Therapeutics. “This is AffaMed’s second biosimilar candidate to receive CTA approval within one-year of founding, accelerating its goal of providing innovative medicines to Chinese patients improving accessibility.”The approved clinical trial is part of Samsung Bioepis’ ongoing global Phase 3 trial, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and the reference product in subjects with paroxysmal nocturnal hemoglobinuria. The trial started in August 2019 and expected to enroll 50 subjects globally. The clinical study preparation in China is on track and first Chinese patient visit is scheduled in Q1 2020.In addition to the SB12 (AMT904), Samsung Bioepis and AffaMed are collaborating across a number of biosimilar candidates in China, including biosimilars referencing Lucentis® (ranibizumab)2 and Eylea®[3] (aflibercept).____________1 Soliris ® is a registered trademark of Alexion2 Lucentis® is a registered trademark of Genentech3 Eylea® is a registered trademark of Regeneron PharmaceuticalsAbout Samsung Bioepis Co., Ltd.Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.About AffaMed TherapeuticsAffaMed Therapeutics is a biopharmaceutical company focused on identifying and licensing late-stage candidates for commercialization in emerging Asia Pacific markets and globally. AffaMed was founded and funded by CBC Group, a healthcare private equity firm focused on the development and late-stage investment opportunities in 2019.About CBC GroupCBC Group is a healthcare dedicated private equity firm, focused on growth and late-stage investment opportunities across the healthcare industry. CBC Group is committed to supporting the commercialization of cutting-edge technologies and companies that fulfill unmet medical needs, thus continuously improving the standard and quality of care for patients.Contacts[Samsung Bioepis] Story continuesNa Yun KIM+82-31-8061-1604nayun86.kim@samsung.comEvelyn Eubene Hong+82-31-8061-1215eubene.hong@samsung.comYoon KIM +82-31-8061-1783yoon1.kim@samsung.com[AffaMed Therapeutics]Media in US:
Mark Corbae Senior Vice President Westwicke PR +1 (203) 682-8288 mark.corbae@icrinc.com
Media in China:
Edmond Lococo Managing Director ICR Asia +86 (10) 6583-7510 edmond.lococo@icrinc.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextKorea Cases Top 2,000; Nigeria Confirms Infection: Virus UpdateBloombergVirus detected in sub-Saharan Africa, global stocks tankAFPVirus game 'Plague' app pulled in China: developerAFPJapan's January factory output beats forecasts but slowdown expectedReutersBTS cancel concerts as South Korea coronavirus cases pass 2,000AFPBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo Finance